Sample Consultative Proteomics® Report

Attached find the first page of a sample 10 page Consultative Proteomics® Report for a patient with Hodgkin’s Lymphoma. In this case, eight molecular protein pathways of importance in the disease were profiled using MorphoproteomicSM Analysis by Immunohistochemistry.

The report includes the following information:
• schematic summary of signal transduction pathways in patient (for select tumors)
• rationale and evidence supporting the proposed therapeutic considerations
• the patient’s tumor profile table with protein scoring, cellular compartment and microanatomical region
• digital images of tumor including H&E and scored protein pathways, along with detailed interpretations
• therapeutic options targeting the pathogenetic and adaptive pathways in the disease
• clinical and/or pre-clinical evidence for the proposed therapies
• summary recommendations
• extensive reference publications
• personal signoffs by the doctors performing the analysis

Focus reports, such as this one, usually analyze around 10 representative proteins. For more comprehensive or follow-up analyses, Consultative Proteomics® Reports examine and interpret around 24 representative proteins, resulting in an extensive document of more than 20 pages. Each report includes up to one hour of follow-up by email or phone with the signoff doctor. Additional time may be arranged as required.

If you are a physician or a patient and would like more information on Consultative Proteomics services, please contact our Coordinator, Ms. Bheravi Patel, at 713-500-5309. E-mail: Bheravi.Patel@uth.tmc.edu. Note that Consultative Proteomics® Reports are often covered by insurance and must be requested in collaboration with the patient’s physician.

For up-to-date news, please visit our website at:
https://med.uth.edu/pathology/clinical-services/consultative-proteomics/

The immunoperoxidase stains reported in Consultative Proteomics® Reports were developed and their performance characteristics determined by the University of Texas Medical School, Pathology Laboratory in Houston, TX. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) as qualified to perform high-complexity clinical testing.
Body Site: Lymph Node

Clinical Data: Now XX year old with a history of chemo-refractory metastatic nodular sclerosing Hodgkin lymphoma. Morphoproteomics requested to define the biology and to determine the state of immune dysregulation and to propose immunomodulating therapies.

Physician(s): Ir.

HODGKIN DISEASE

Schematic summary supporting immune dysregulation in patient XXX’s as a component of his/her recurrent/refractory Hodgkin Disease. Opportunities for therapeutic intervention targeting immune dysregulation, as a pathogenetic factor include vorinostat and rapamycin (sirolimus). There are detailed and rationale provided in the narrative report which follows. Legend: ➔ Stimulates, ▼ Inhibits

©2006–2014 RE Brown